弥漫性桥脑胶质瘤:缩短还是延长放疗疗程?
研究回顾性分析2010年4月至2020年2月MAHAK中心108例弥漫性内生型桥脑胶质瘤患者,比较低分割放疗与常规分割放疗对总生存的影响。中位总生存9.6个月,分割方式无显著影响;化疗无获益。年龄>4岁、症状持续时间<3个月、同时出现三联征及无脑积水为不良预后因素(p<0.05)。作者提出基于预后因素的评分系统以指导放疗分割选择。
要点
- 低分割放疗与常规分割放疗对总生存无显著影响,中位OS为9.6个月。
- 年龄>4岁、症状<3个月、三联征、无脑积水为不良预后因素(p<0.05)。
- 作者提出评分系统指导低分割与常规分割的选择,但需外部验证。
核心结论
- 低分割放疗与常规分割放疗对总生存无显著影响,中位OS为9.6个月。
- 不良预后患者因预期寿命短可能从低分割放疗中获益,作者提出评分系统指导分割选择。
研究设计与样本
- 回顾性研究,纳入2010年4月至2020年2月MAHAK中心108例弥漫性内生型桥脑胶质瘤患者。
- 诊断基于临床症状和MRI,活检非强制;34例(32%)接受活检,其中18例(53%)为高级别胶质瘤或胶质母细胞瘤。
主要发现
- 不良预后因素包括年龄>4岁、症状持续时间<3个月、同时出现三联征及无脑积水(p<0.05)。
关键数值与推荐
- 低分割放疗可缩短治疗时间、减少住院次数和费用,尤其适用于中低收入国家。
- 许多中低收入国家机构仍使用54 Gy/30次;作者提出基于预后因素的评分系统指导低分割与常规分割的选择。
临床怎么用
- 对预后不良的弥漫性内生型桥脑胶质瘤患者,可考虑低分割放疗以改善生活质量并降低医疗资源负担。
- 临床可参考年龄、症状持续时间、三联征及脑积水等预后因素进行风险分层,辅助放疗分割决策。
局限性
- 回顾性研究,样本量有限(108例),仅部分患者接受活检和分子检测。
- H3K27M突变仅2例检测,其余未评估;评分系统需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diffuse intrinsic pontine glioma is a lethal disease with a median overall survival (OS) of less than one year. Currently, no curative treatment exists, and radiotherapy primarily aims for symptom palliation. Hypofractionated radiotherapy (HR) has been proposed to enhance quality of life through shorter treatment duration, fewer hospital visits, and reduced costs, particularly in low- and middle-income countries (LMICs). However, many LMIC institutions continue to use 54 Gy in 30 fractions. The study aims to identify patients who may benefit from HR. METHODS: We reviewed data from MAHAK patients treated between April 2010 and February 2020. Diagnosis was based on clinical symptoms and MRI imaging; biopsy was not mandatory. RESULTS: Among 108 identified patients, 34(32%) underwent a biopsy, with high-grade glioma or glioblastoma diagnosed in 18(53%). H3K27M mutation was found in two patients, while others were not evaluated. No seeding was detected at diagnosis. Thirty-one patients (29%) received 50-54 Gy using normal fractionation, while the remainder received HR. Median OS was 9.6 months (range 1-67). No significant impact of fractionation was observed. Seventy-eight (72%) patients received chemotherapy, which showed no benefit. Eleven patients received re-irradiation at progression, showing a post-progression OS of 6 months. Poor-risk factors included age over 4 years, symptom duration < 3months, simultaneous triad signs, and absence of hydrocephalus (p < 0.05). CONCLUSION: Given their shorter life expectancy, poor-risk patients may benefit from HR. We propose a scoring system based on prognostic factors to guide decisions between HR and normal fractionation.
引用
- Ghalibafian M, Mirzaei S, Sadeghi Y, et al. Diffuse pontine glioma (DPG): shorter or longer treatment time? J Neurooncol. 2025. PMID: 41134453. doi:10.1007/s11060-025-05308-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。